Standard-Dose Osimertinib in EGFR-Mutated Non–Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease
Luke S. McLean, Wasek Faisal, Sagun Parakh et al. · JCO Precision Oncology · 2021
PURPOSE: Leptomeningeal disease (LMD) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma is associated with a poor prognosis and limited treatment options. Osimertinib is a potent third-generation EGFR tyrosine kinase inhibitor with confirmed CNS penetration. This study reports on outcomes of patients with EGFR-mutated non-small-cell lung cancer who developed LMD and were subsequently treated with osimertinib. METHODS: We identified patients treated with osimertinib 80 mg PO daily under a compassionate access scheme across nine tertiary Australian institutes between July 2017 and July 2020. Patient demographics, tumor characteristics, and treatment history were collected. Median overall survival, median progression-free survival, disease control rates (DCR), and overall response rates (ORR) were assessed. Kaplan-Meier analysis was performed and descriptive statistics were used. RESULTS: Thirty-nine patients were analyzed of which 74% were female. Exon 19 deletions (49%) and L858R point mutations (41%) were the most common EGFR mutations. Forty-nine percentage of patients were Eastern Cooperative Oncology Group 1. The median duration of osimertinib therapy was 6 months. The extracranial DCR and ORR were 60% and 54%, and the intracranial DCR and ORR were 68% and 53%, respectively. Median overall survival was 10.5 months (95% CI, 8.17 to 15.05 months). CONCLUSION: There are limited treatment options for LMD in EGFR-positive lung cancer, and osimertinib at a dose of 80 mg daily is an active therapeutic option for these patients.
Cited by 10 works. doi:10.1200/po.20.00464
Authors
- Luke S. McLean
- Wasek Faisal
- Sagun Parakh
- Steven Chuan-Hao Kao
- Craig R. Lewis
- Melvin T.M. Chin
- Mark Voskoboynik
- Malinda Itchins
- Ross R. Jennens
- A. Broad
- Benjamin Solomon
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Comprehensive molecular profiling of lung adenocarcinoma
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer